CHOLESTAGEL Health Economics Study México March 7, 2008.

Slides:

Advertisements

Similar presentations

Time line of data collection in the Nurses’ Health Study, 1988 to 2000 A. Heather Eliassen et al, Arch Intern Med. 2005; 165:

Advertisements

Pathway of Exogenous Cholesterol Metabolism

1 MT vs CT: 28 day survival Number at risk CT MT day % Surviving Monotherapy.

The Contribution of Health Economics to Health in the United States Mark McClellan, MD, PhD Brookings Institution.

SECONDARY PREVENTIONS Jaimon Stucki MS-1 PSCOM. Blood Draw.

Slide 1 Downloaded from Ezetimibe Factorial Coadministration Studies.

C. Baigent, et al. on behalf of the SHARP Investigators Lancet 2011;Epub 9 June.

David J. Graham et al. JAMA, 2004; 292: 2585 Description of Inception Cohorts for Patients Using Statin and Fibrate Drug Therapy.

Yunoki K et al. Atherosclerosis 2011 Epub Apr 22.

TREATED AS CONSUMPTION: HERE NOW, GONE TOMORROW ACTUALLY, A DURABLE GOOD: LONG-LASTING VALUE.

Shalev V, et al. Arch Intern Med 2009; 169:

THE DIABETES PREVENTION PROGRAM RESEARCH GROUP*

Ezetimibe Overall Conclusions

Demographic Characteristics of Individuals With AERS of Rhabdomyolysis, Proteinuria/Nephropathy, or Renal Failure (COMPOSITE AERS) Alsheikh-Ali AA et al.

Flow Diagram of Identification of Randomized Trials for Inclusion Goran Bjelakovic, et al. JAMA. 2007;297:

Downloaded from Slide 1 Dual Inhibition of Two Sources of Cholesterol: Absorption and Production Results of a Clinical Trial.

Doc.: IEEE /1583r1 Submission November 2011 Osama Aboul-Magd (Huawei Technologies)Slide 1 TGac November 2011 Closing Report Date: Authors:

Department Of Agriculture PROVINCE OF THE EASTERN CAPE.

Jan 2016 Solar Lunar Data.

Westerweel PE et al. Eur Heart J 2008;29:

Flowchart of participants

Baseline Characteristics of 167 Patients Randomly Assigned to Either Placebo or Extended-Release Niacin Allen J. Taylor et al. Circulation 2004; 110:

Characteristics of the Folic Acid and Placebo Groups at the Start of the Study J. Durga et al. Arch Intern Med. 2005;165:

Mean 24-Hour, Daytime, and Night Ambulatory Systolic BP, Diastolic BP, and PP Before (Week 0) and After (Week 12) NAG and Placebo Intake in 37 Hypertensive.

Vitamin D3 increased ASL antimicrobial activity.

GAUSS-3 Trial design: Patients with objective evidence of intolerance to statin agents were randomized in a 2:1 fashion to either evolocumab 420 mg subcutaneously.

GLAGOV Trial design: Patients with CAD and elevated LDL cholesterol on statin therapy were randomized to subcutaneous evolocumab (n = 484) vs. subcutaneous.

Differences in awareness, treatment, and control of hypertension between Southerners and non-Southerners Hypertension awareness, treatment, and control.

LEVO-CTS Trial design: Patients undergoing cardiac surgery with the use of cardiopulmonary bypass were randomized to infusion of levosimendan 0.2 µg/kg/min.

EVITA Trial design: Smokers admitted with an acute coronary syndrome were randomized to varenicline 1 mg twice daily (n = 151) vs. placebo (n = 151). Study.

Pharmacist Perspectives on Novel Agents in Multiple Myeloma

2013 VFC PRESIDENT’S REPORT

Atorvastatin for Reduction of Myocardial Damage During Angioplasty

Assembled by the Rubicon Forest Protection Group

Relative risk of major events with atenolol vs placebo

Selmer R, et al. Br J Clin Pharmacol 2009;67:355-62

مديريت موثر جلسات Running a Meeting that Works

Some Caveats: Sabotage, Collusion, and Risk Taking in Tournaments

Treatment EPO (1 IU/ml) Placebo

The means and SDs of the data from all Glucommander runs from 1984 to 1998 are graphed. The means and SDs of the data from all Glucommander runs from 1984.

FOURIER Trial design: Patients with established cardiovascular disease on statin therapy were randomized to evolocumab 140 mg subcutaneous every 2 weeks.

Screening, Lipid Stabilization, and Placebo Run-in

Efficacy and safety of niacin/laropiprant

Forest plot of risk ratio with its 95% CI for the incidence of contrast-induced nephropathy among patient taking statin versus control based on renal impairment.

Sudhop T. et al. J Lipid Res 2009 Apr 20 [Epub ahead of print]

HARMONIZE Trial design: Patients with hyperkalemia (K ≥5.1 mEq/L) were randomized in a 1:1:1:1.7 fashion to receive sodium zirconium cyclosilicate (ZS)

A connectionist model in action

Number of Monthly Ezetimibe Prescriptions in the United States and Canada from 2002 to 2006 Data are from the National Prescription Audit of IMS Health.

RUTHERFORD-2 Trial design: Patients with heterogeneous familial hypercholesterolemia (HeFH) on statins were randomized in a 2:2:1:1 fashion to subcutaneous.

Baseline Demographic Characteristics of Adults With Diagnosed Heart Failure and Eligible to Receive Lipid-Lowering Therapy Alan S. Go, et al.

Tremblay AJ. Et al. J Lipid Res 2009 Mar 22 [Epub ahead of print]

Change from baseline in the severity of morning cough and severity of difficulty bringing up phlegm in the morning over the study period in the active-comparator.

Base: Adults with any chronic condition

Characteristics of Large Randomized Controlled Statin Trials Included in the Present Analysis Alawi A. et al. JACC 2008 Aug 20 [Epub ahead of print]

Figure 1 Annualized percentage brain volume change

Change in APOC3 level in response to treatment with APOC3 antisense oligonucleotide ISIS Phase 2, randomised, double-blind, placebo-controlled study.

(A) Target 1 vs Target 2 - % of those diagnosed vs % of those diagnosed receiving ART. (B) Target 2 vs Target 3 - % of those diagnosed on ART vs % of those.

Illustration of a trial design to help evaluate the clinical accuracy of a test of ischaemia. Illustration of a trial design to help evaluate the clinical.

Recurrence of HF hospitalization Total-time approach

Treatment response patterns and effect size over time in exclusively placebo-controlled trials. Treatment response patterns and effect size over time in.

Effects of GIP and GLP-1 infusion on MR-proANP levels.

Changes in glycated hemoglobin (HbA1c) levels after 12 weeks’ treatment with lixisenatide (according to dose increase regimen) or placebo. Changes in glycated.

Effects of vinegar (□) and placebo (⧫) on plasma glucose (A–C) and insulin (D–F) responses after a standard meal in control subjects, insulin-resistant.

John H. Straus et al. Health Affairs

(A) Proportion of residents receiving prescriptions for antipsychotics, statins, benzodiazepines and trazodone each month, Ontario, Canada (October 2013.

Effect of methylprednisolone versus placebo on the risk of acute kidney injury in a subsample of patients with serial postoperative serum creatinine assessments.

PHOENIX I: PASI 75 Response After 12 Weeks

Spasticity as measured by mean combined scores on the modified Ashworth scale, before and after treatment, on each day of each phase of the trial. Spasticity.

26 Oct 2017 – May 2019 Well water level monitoring data

Presentation transcript:

CHOLESTAGEL Health Economics Study México March 7, 2008

Health Economics Perspectives –No treatment (Davidson et al., Insull et al.) –Statin + placebo (Hunninghake et al., Knapp et al.) –Ezetimibe + placebo (Bays et al., Zema et al.) –Statin + EZE + placebo (no data available) Cholestagel monotherapy Statin + Cholestagel Ezetimibe + Cholestagel Statin + EZE + Cholestagel VS

FebMarAprMayJun 2009 Run Data Regulatory Affairs Time Line Health Economic Study Jan Inputs to K.Brito Guiamark Regulatory Affairs New Prod Especial. New Input: Statin + Cholestagel vs Statin + Placebo Dec Run Data Regulatory Affairs Finaly Report Conference Call (Mar 12,’08) To Define: - Ezetimibe + Cholestagel - Statin + Cholestagel 2008